Nov 30, 2023 8:00am EST FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Nov 08, 2023 4:01pm EST Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
Nov 01, 2023 8:00am EDT Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
Oct 10, 2023 8:00am EDT Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
Oct 03, 2023 8:00am EDT Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Sep 25, 2023 8:30am EDT Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Sep 18, 2023 9:00am EDT Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Aug 31, 2023 8:00am EDT Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
Aug 28, 2023 8:00am EDT Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Aug 14, 2023 8:30am EDT Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
